https://www.selleckchem.com/pr....oducts/NVP-AUY922.ht
The COVID-19 pandemic struck an immunologically naïve, globally interconnected population. In the face of a new infectious agent causing acute respiratory failure for which there were no known effective therapies, rapid, often pragmatic trials were necessary to evaluate potential treatments, frequently starting with medications that are already marketed for other indications. Early in the pandemic, hydroxychloroquine and azithromycin were two such candidates. Assess the relative efficacy of hydroxychloroquine and azithromycin among h
Like
Comment
Share
